Analysts Set AstraZeneca plc (AZN) PT at $5,249.18

Shares of AstraZeneca plc (LON:AZN) have been given a consensus rating of “Hold” by the twenty-one research firms that are presently covering the firm, reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 4,832.56 ($62.93).

Several equities analysts recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating and issued a GBX 5,600 ($72.93) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.07) target price on AstraZeneca plc and gave the stock a “neutral” rating in a report on Tuesday, June 27th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Barclays PLC restated an “overweight” rating and set a GBX 6,000 ($78.14) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Monday, June 5th.

Shares of AstraZeneca plc (LON AZN) traded down 0.96% during mid-day trading on Friday, hitting GBX 4384.00. 1,583,746 shares of the company were exchanged. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s market cap is GBX 55.50 billion. The stock’s 50-day moving average price is GBX 4,945.31 and its 200 day moving average price is GBX 4,856.38.

The business also recently declared a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be paid a GBX 68.90 ($0.90) dividend. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).

WARNING: “Analysts Set AstraZeneca plc (AZN) PT at $5,249.18” was first reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply